Evidence map›Paper›PMID 39117945›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2024

Rationality and implication of catheter-based adrenal ablation for bilateral primary aldosteronism.

Fang Sun, Hexuan Zhang, Hongbo He, Qiang Li, Zhigang Zhao, Nan Jiang, Xiaona Bu, Xiaoli Liu, Zhencheng Yan, Zhiming Zhu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fang SunDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Hexuan ZhangDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Hongbo HeDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Qiang LiDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Zhigang ZhaoDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Nan JiangDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Xiaona BuDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Xiaoli LiuDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Zhencheng YanDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China.
Zhiming ZhuDepartment of Hypertension and Endocrinology, Daping Hospital, Army Medical, University of PLA, Center for Hypertension and Metabolic Diseases, ChongqingInstitute of Hypertension, Chongqing, 400042, China. hbpcms@sina.com.
Chongqing Endocrine Hypertension Collaborative Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mineralocorticoid receptor antagonists (MRAs) for bilateral primary aldosteronism (PA) are the mainstay option recommended by guidelines, but poor compliance occurs due to numerous side effects. We aimed to examine whether catheter-based adrenal ablation could be an alternative treatment for bilateral PA.644 PA patients were included from a total of 6054 hypertensive patients. Adrenal CT scan and adrenal venous sampling (AVS) were both performed for PA subtype classification. Clinical and biochemical outcomes were assessed at 6 months after treatment according to the Primary Aldosteronism Surgical Outcome (PASO) criteria.93 patients with PA were recruited to be treated by adrenal ablation, including 25 bilateral PA and 68 unilateral PA according to AVS results. Office SBP and DBP significantly decreased from baseline levels, serum potassium levels increased and ARR significantly decreased (p < 0.01) in both the bilateral and unilateral groups. In the bilateral group, complete, partial and absent clinical success was achieved in 6 (24.0%), 11 (44.0%) and 8(32.0%) patients, respectively. In the unilateral group, complete, partial and absent clinical success was achieved in 12 (17.6%), 37 (54.4%), and 19 (27.9%) patients, respectively. The numbers of patients achieving complete, partial, and absent biochemical success were 15 (60.0%), 6 (24.0%), and 4 (16.0%), respectively, in the bilateral group versus 37 (54.4%), 9 (13.2%), and 22 (32.3%), respectively, in the unilateral group. In conclusion, we provide evidence for the beneficial outcomes of unilateral adrenal ablation for patients with bilateral PA. Our findings provide insight into an alternative option for patients with bilateral excess aldosterone.

Indexed as

Adrenal GlandsCatheter AblationHyperaldosteronismAdrenalectomyAdultAgedAldosteroneFemaleHumansHypertensionMaleMiddle AgedTreatment OutcomeAldosteroneAdrenal ablationAdrenal venous sampling (AVS)Bilateral primary aldosteronismHypertensionPrimary aldosteronism (PA)

Identifiers

PMID39117945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.